{"nct_id":"NCT06345729","title":"A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","status":"RECRUITING","status_verified_date":"2025-10","start_date":"2024-05-24","start_date_type":"ACTUAL","primary_completion_date":"2029-02-19","primary_completion_date_type":"ESTIMATED","completion_date":"2031-02-18","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}